By
Emily Mullin
Published: Feb. 25, 2014, 11:38 p.m.·
Tags:
Pharma industry,
Research and development
Last month AstraZeneca said it is shuttering an Indian research site as it moves away from neglected diseases to focus on areas with more potential for growth. With the site shutdown, the company plans to pull out of early-stage research on tropical diseases, tuberculosis and malaria but spare AZD5847, a TB treatment currently in Phase II development.
Read More →
